of Sandu Pharmaceuticals Limited for FY 2024-25
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sandu Pharmaceuticals Limited has filed its 40th Annual Report for FY 2024-25 with BSE, along with the notice for its 40th Annual General Meeting scheduled on 30th September 2025 at 4:30 PM via video conferencing. Per the Chairman's address, the company's revenue stood at ₹6,719.24 lakhs, a marginal decline of 0.13%, while net profit grew 4.02%, indicating improved margins. The Board has recommended an 8% dividend (₹0.80 per share on ₹10 face value), subject to shareholder approval at the AGM. Key agenda items include reappointment of Shri Shashank Sandu (retiring by rotation), approval of material related party transactions with Sandu Brothers Private Limited up to ₹100 crore, appointment of M/s Swapnil J Dixit & Associates as Secretarial Auditor for a five-year term, and continuation of CFO Shri Vijay Kajarekar beyond age 70. The filing also notes the resignation of Shubhada P. Sandu as Director effective 13 February 2025.
Marginal revenue dip with profit growth signals operational efficiency rather than expansion. The modest 8% dividend offers limited yield but reflects stable shareholder returns. The ₹100 crore related party transaction cap with promoter-group entity Sandu Brothers Private Limited is a key governance point shareholders should review before voting.